40+
Studies delivered
Home/Track Record
Experience & Portfolio
Over a decade of studies delivered for the world's leading sponsors.
Sponsors have returned to Botho Ke Bontle for two, three, or more consecutive studies, the most reliable indicator of site quality and sponsor confidence.
14
International sponsors
4
Active studies
5
In start-up
Active
Currently in progress
| Study | Sponsor | Status |
|---|---|---|
| PF-07321332 / Ritonavir: Paediatric Participants Phase 2/3, Open-Label | Pfizer | Ongoing |
| mRNA-1345 RSV Vaccine: Pregnant Women Phase 2, Observer-Blind | Moderna | Ongoing |
| CagriSema 2.4 mg / 2.4 mg: Overweight / Obesity Phase 3 | Novo Nordisk | Ongoing |
| DR-0201: Autoimmune Rheumatic Diseases Phase 1, Basket Study | Sanofi | Ongoing |
Completed
Successfully delivered
A selection from more than 40 studies delivered for international sponsors since 2014.
| Study | Sponsor |
|---|---|
| COVID-19 mRNA Vaccine (BNT162b2): Pregnant Women Phase 2/3 | Pfizer / BioNTech |
| PF-07321332 / Ritonavir: Household Contacts Prevention Phase 2/3 | Pfizer |
| PF-07321332 / Ritonavir: High-Risk Adults Phase 2/3 | Pfizer |
| PF-07321332 / Ritonavir: Low-Risk Adults Phase 2/3 | Pfizer |
| RSV Prefusion F Subunit Vaccine: Adults Phase 3 | Pfizer |
| BNT162 Multivalent mRNA Vaccine: Healthy Subjects Phase 2 | BioNTech / Pfizer |
| BNT162b2 Additional Doses: Master Protocol Phase 3 | Pfizer / BioNTech |
| BNT162b2 Adapted Variants: Healthy Children Phase 1/2/3 | Pfizer / BioNTech |
| RSV Prefusion F Vaccine: Pregnant Participants Living with HIV Phase 3 | Pfizer |
| Modified mRNA Influenza Vaccine vs. Licensed IIV: Adults Phase 3 | Pfizer |
| Semaglutide 2.4 mg: Obesity & Knee Osteoarthritis | Novo Nordisk |
| Insulin Icodec Once-Weekly vs. Glargine: Type 2 Diabetes | Novo Nordisk |
| QIVc Influenza Vaccine: Children 6–47 Months Phase 3 | Seqirus |
| BLU-5937: Refractory Chronic Cough (CALM-1) Phase 3 | Bellus Health |
| ABI-2280 Vaginal Tablet: Cervical SIL Phase 3, Open-Label | Antiva Biosciences |
| RSV Vaccine: Infants & Toddlers (VAD00004) Phase 3 | MedImmune / AstraZeneca |
Upcoming
In start-up
| Study | Sponsor | Expected start |
|---|---|---|
| CHF5993 pMDI: Mild / Moderate Asthma Phase 2, Therapeutic Equivalence | Chiesi | Jul 2026 |
| RO7795068: Overweight / Obesity + ASCVD Phase 3, Placebo-Controlled | F. Hoffmann-La Roche | Sep 2026 |
| RO7795081: Overweight / Obesity + Type 2 Diabetes Phase 3 | F. Hoffmann-La Roche | Jan 2027 |
| Verekitug: Severe Asthma (Adolescents & Adults) Phase 3 | Upstream Bio | Jan 2027 |
| Acne Vulgaris: Randomized, Vehicle-Controlled Double-Blind, Multicenter | AOBiome | Feb 2027 |
Pharmaceutical Partners
Fourteen international sponsors
B2KB has been engaged by and successfully delivered clinical research for 14 international pharmaceutical organisations across Phase 1–4 studies.
Sponsor qualification by these organisations reflects a track record of protocol adherence, data integrity, regulatory compliance, and patient-centred research conduct.
Add your study to our portfolio
We welcome CROs and sponsors seeking a reliable, growth-oriented research partner in South Africa.